Dallas, TX April 11, 2016 – Cerebain Biotech (OTCQB: CBBT) today announced that the company has appointed Azad L. Sheikh, MBBS, MRCP (UK), FRCP (C), MBA, to its Scientific Advisory Board.
Dr. Sheikh is the Regional Medical Director and Critical Care Physician at Anderson Luchetti Women’s and Children’s Center at Sutter Medical Center Sacramento. His core competences include managing physician relationships, developing strategic partnerships, assisting with fund raising, creating a culture of clinical excellence and building relationships with executive decision makers.
“Dr. Sheikh’s business, research, and clinical expertise and experience will be instrumental in our continuing, progressive and exciting advancement in our treatment of Alzheimer’s disease,” stated Eric Clemons, president and CEO of Cerebain Biotech. “We are extremely pleased to welcome him to our Scientific Advisory Board”.
About Cerebain Biotech Corp.
Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations.
Forward Looking Statements
This news release contains certain “forward- looking statements.” Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company’s control. The forward-looking statements are also identified through the use of words “believe,” enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company’s reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.